Sera Prognostics (SERA) Corporate presentation summary

Vision and market need

• Aims to become a global leader in women's health diagnostics by providing pivotal information to improve maternal and neonatal outcomes and healthcare economics.

• Preterm birth rates in the US have risen from 9.4% to 10.4% between 2013 and 2024, with NICU admissions increasing from 8.7% to 9.8%.

• Preterm births account for 61% of neonatal costs, with extremely premature births costing up to $344,355 per delivery and 7x higher healthcare costs over 7 years.

• Traditional screening methods miss 81% of women who will experience preterm birth, and only 20% of mothers receive information on preterm labor risk at their first prenatal appointment.

Product and scientific foundation

• PreTRM is a proteomics-based, blood test that predicts spontaneous preterm birth risk early in pregnancy, using biomarkers IGFBP4 and SHBG.

• The test is clinically validated, integrates into standard prenatal workflows, and delivers results within seven business days.

• Supported by 11+ published studies, a biobank of 20,000 samples, and advanced AI/machine learning for risk prediction.

• PreTRM is the only clinically validated test for early prediction of premature birth, verified by 8 independent clinical studies.

Clinical evidence and outcomes

• PRIME and AVERT studies demonstrate that PreTRM-guided interventions reduce preterm births and neonatal complications.

• PRIME study (n=5,018) showed 20% fewer NICU admissions, 56% fewer births before 32 weeks, and 32% fewer before 35 weeks.

• Each day of gestational age gained reduces complications; the earliest 10% of births were prolonged by 4.5 days on average.

• Targeted interventions for higher-risk moms include low-dose aspirin, vaginal progesterone, and care management.